Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2019-09-20 Capital/Financing Update
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 95% confidence The document is a disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details an incremental investment in Stelis Biopharma Private Limited by Strides Pharma Science Limited. The content focuses on the transaction specifics such as the target entity, nature of consideration, percentage of shareholding, and cost of acquisition. There is no financial report, earnings data, or management discussion. The document is an announcement of a capital investment transaction, which fits the category of Capital/Financing Update (CAP). The document length is 4014 characters, which is sufficient to provide substantive details about the transaction rather than just a brief announcement. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2019-09-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release issued by Strides Pharma Science Limited announcing the Board of Directors' approval of incremental investments in Stelis Biopharma Private Limited. It details the investment amount, business strategy, and outlook for Stelis, including future growth plans and operational milestones. The document is not a financial report, earnings release, or regulatory filing but a corporate announcement about financing and strategic investment decisions. It does not contain financial statements or detailed financial data but focuses on capital infusion and business strategy. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8012 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2019-09-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Strides Pharma Science Limited's acquisition of a strategic stake in Fairmed Healthcare AG. It includes detailed information about the transaction, such as the percentage of shares acquired, cost, and strategic rationale. The document also contains a disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is a regulatory requirement for material events like acquisitions. The content focuses on the acquisition transaction and related disclosures rather than financial results, management changes, or other report types. Therefore, this document fits best under Capital/Financing Update (CAP), as it provides an update on a significant capital transaction (acquisition). The document length is sufficient and contains substantive information about the transaction, not merely an announcement of a report or a brief notification.
2019-09-11 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the acquisition of a USFDA approved manufacturing facility by Strides Pharma Science Limited. It provides details about the acquisition, strategic rationale, and company background. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is an announcement of a corporate event related to capital assets but does not discuss financing activities like fundraising or capital structure changes. It is not a full financial report, audit, or earnings release. The content fits best under a Capital/Financing Update as it informs about a significant acquisition impacting the company's capital assets and operations.
2019-08-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a US FDA inspection at the company's manufacturing facility with zero 483 observations. It is dated August 9, 2019, and is addressed to stock exchanges. The content is a corporate announcement about operational compliance and inspection results, not a financial report, earnings release, or regulatory filing. The document length is 3600 characters, which is relatively short and typical for a press release. There is no detailed financial data, no voting results, no management changes, no legal proceedings, or other report types. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2019-08-09 English
Updates
Regulatory Filings
2019-08-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.